![Peter Swetly](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Swetly
Corporate Officer/Principal bei University of Vienna
Aktive Positionen von Peter Swetly
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
University of Vienna | Corporate Officer/Principal | 20.01.2010 | - |
Karriereverlauf von Peter Swetly
Ehemalige bekannte Positionen von Peter Swetly
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Boehringer Ingelheim GmbH
![]() Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
ORIDIS Biomed Forschungs & Entwicklungs GmbH
![]() ORIDIS Biomed Forschungs & Entwicklungs GmbH Medical SpecialtiesHealth Technology ORIDIS Biomed - a specialist in tissue-based cancer research - is a Contract Research Organization founded in 2001 as a spin-off from the Medical University of Graz. Based on its unique clinical and biobank network and its sound molecular pathological expertise ORIDIS Biomed designs and performs retrospective and prospective customized tissue- and body fluid- based studies. The company brings value to its customers by evaluation of the medical and clinical relevance of drug targets, mode-of-action models and biomarker candidates for patient stratification and diagnosis. ORIDIS Biomed's unique offering combines its proprietary TISSOMIC research platform and proven experience in analysis of clinically relevant tissue with access to a biobank with 2.9 million samples of diseased human tissue and associated data. Research activities at ORIDIS Biomed are focused on the validation and development of tissue- and blood-based nucleic acid biomarkers for early cancer diagnosis, patient stratification and therapy monitoring. | Gründer | 20.01.2010 | - |
Statistik
International
Österreich | 3 |
Deutschland | 2 |
Operativ
Founder | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
ORIDIS Biomed Forschungs & Entwicklungs GmbH
![]() ORIDIS Biomed Forschungs & Entwicklungs GmbH Medical SpecialtiesHealth Technology ORIDIS Biomed - a specialist in tissue-based cancer research - is a Contract Research Organization founded in 2001 as a spin-off from the Medical University of Graz. Based on its unique clinical and biobank network and its sound molecular pathological expertise ORIDIS Biomed designs and performs retrospective and prospective customized tissue- and body fluid- based studies. The company brings value to its customers by evaluation of the medical and clinical relevance of drug targets, mode-of-action models and biomarker candidates for patient stratification and diagnosis. ORIDIS Biomed's unique offering combines its proprietary TISSOMIC research platform and proven experience in analysis of clinically relevant tissue with access to a biobank with 2.9 million samples of diseased human tissue and associated data. Research activities at ORIDIS Biomed are focused on the validation and development of tissue- and blood-based nucleic acid biomarkers for early cancer diagnosis, patient stratification and therapy monitoring. | Health Technology |
Boehringer Ingelheim GmbH
![]() Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
- Börse
- Insiders
- Peter Swetly
- Erfahrung